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A b s t r a c t  
The present study pertains to the delivery of antimalarial drug (Lumifantrine). In this, 
polyphosphazene has been used in the synthesis of polyphosphazene-linked conjugates of 
Lumifantrine. These polymer-linked Conjugates have been synthesized and characterized by 
modern analytical techniques. The in-vitro drug release of Lumifantrine drug conjugates: p-Amino 
benzoic acid ester substituted polyphosphazene drug conjugate (15) and Glycine methyl ester 
substituted polyphosphazene drug conjugate (21) have been found to be 6.00 % and 5.96% (pH 
1.2), 88.52% and 79.86% (pH7.4), respectively. These drugs conjugate may prove an effective 
delivery system for the treatment of malaria. 
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Introduction 
Incidence, Prevalence and Survival 
Almost one-half of the world’s population lives under the constant 
threat of malaria, and the disease is responsible for about 2 million 
deaths each year [1].  A large percentage of the fatalities occur in 
Africa; however, malaria is endemic throughout most of South East 
Asia, the Indian subcontinent, the South Pacific region, and Latin 
America. Malaria is caused by protozoan parasites of the genus 
Plasmodium. There are four species of Plasmodium that infect 
humans, the most deadly of these being Plasmodium falciparum. 
The parasite requires two hosts, a female Anopheles mosquito and 
a human. There were an estimated 0.881 million deaths worldwide 
in 2006, of which 90% were in the African region and 4% in each of 
the South-East Asia and the Eastern Mediterranean regions. The 
individual most at risk of significant morbidity and mortality owing to 
malaria are the children under the age of 5 years and the pregnant 
women [2, 3]. New empirical estimates put the number of episodes 
of clinical Plasmodium falciparum malaria in the region of half a 
billion per year [4]. The mortality rate from malaria has been 
estimated at approximately 2.7 million per year, with over 75% of 
these deaths occurring in African children [5]. Unfortunately, these 
staggering figures are on the increase largely as a result of parasite 
multi-drug resistance [6]. The introduction of chloroquine in the 
1940s had a marvelous impact on global health; however, today 
resistance to the drug has been observed in every region where 
Plasmodium falciparum occurs [7]. 
Malaria Life Cycle 
 
The life-cycle of malaria begins by the bites of an infected female 
mosquito by her prey, withdrawing blood and at the same time 
injecting sporozoite-containing saliva into the capillaries of the skin. 
The sporozoites enter liver cells and multiply to form about 30,000 
merozoites each. After about 5 days, the merozoites are released 
into the blood stream. They enter into red blood cells and develop 
through the so-called ring, trophozoite, and schizont stages. The 
erythrocyte provides the parasite with a safe haven from the host’s 
immune system, but presents certain logistical problems with regard 
to access to nutrients and disposal of waste products [8]. 
Parasite growth is supported by host hemoglobin ingestion. During 
a 48-hr (or 72-hr for Plasmodium malariae) cycle the parasite 
divides to produce 16–20 daughter merozoites. The merozoites 
burst from the mature schizont and releasing cell debris, which 
causes a febrile episode in the host. After that the merozoites 
invade new red blood cells and the cycle continues. After several 
cycles, some of the intra-erythrocytic parasites develop into sexual 
stage gametocytes.  When a mosquito bites an infected individual 
the gametes are ingested. They mate in the gut of the insect and 
then pass through the gut wall, where they develop into oocysts that 
release sporozoites that migrate to the salivary glands to be passed 
on to another individual. Due to complication of infections with 
Plasmodium falciparum most of the deaths are occur, where by 
erythrocytes infected with mature-stage parasites adhere to the 
vascular endothelium of post-capillary venules, particularly in the 
brain. Vascular occlusion and/or an inappropriate host immune 
reaction can lead to coma. Once a coma is established in malaria 
patient, the patient has only a 10–50% chance of survival, even with 
optimal medical care also. Whilst the blood forms of the parasite 
cause most of the pathology of the disease, they are also the 
stages that are most susceptible to attack by antimalarial drugs. 
Therefore, there is direct need for the novel effective antimalarial 
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drugs and also various approaches which may not result into drug 
resistance. Plasmodium falciparum is the most common causative 
parasite of malaria [9]. Taking into consideration emergence of 
drug-resistant strains of malarial parasite, it was considered of 
interest to evolve antimalarial drug delivery systems which will not 
lead to drug-resistance and expected to be more effective on 
account of multi-targeted specificity against the malarial parasite 
located in blood, tissue and brain [10].  
Polyphosphazenes 
Polyphosphazenes are polymers with an inorganic backbone 
composed of alternating nitrogen and phosphorus atoms linked by 
alternating single and double bonds, with two substituent’s at each 
phosphorus atom. Although polyphosphazene chemistry has been 
intensively investigated only in mid 1950’s the preliminary 
groundwork was laid down during the 19th century. In 1834, Liebig 
and Wohler obtained a small amount of 
hexachlorocyclotriphosphazenes (11) from the reaction of 
ammonium chloride with phosphorus pentachloride [11]. This is the 
most versatile class of inorganic polymers because a tremendous 
variety of substituent’s can be attached to the backbone 
phosphorus atoms, thus resulting in a very broad spectrum of 
chemical and physical properties which make them suitable for 
many applications. This widespread tailor ability of properties has 
led to many potential applications such as specialty elastomers, 
vibration shock mounts, solid phase electrolytes, biostructural 
materials and polymeric drug-delivery systems [12]. The main 
advantages of these polymers come mainly from variable properties 
and can be designed and prepared by nucleophilic substitution of 
polydichlorophosphazene with various pendent groups [13]. This 
include from hydrophobic groups that confer water insolubility and 
protect the backbone against hydrolysis through groups that 
generate water solubility together with hydrolytic stability to side 
groups that  provide a facile pathway to hydrolytic breakdown of 
polymers to innocuous, excretable or metabolizable small molecules 
[14]. It is colorless, with glass transition temperature (Tg) of 63C 
[15]. It is amorphous at room temperature in an unstretched state 
showing rubbery characteristic [16]. but crystalline at low 
temperature or when stretched [17]. 
Material and Method 
Material used 
Antimalarial drug Lumifantrine was obtained as a gift sample from 
Alkem Laboratories limited Navi Mumbai- 410208 India. Drug 
sample was characterized according to standard procedures. All 
other chemicals were used without further purification.  
 
Methodology 
Preparation of Polymer -Drug Conjugate of p-Amino 
benzoic acid ester 
 
Procedure for esterification of p-Amino benzoic acid  
 
P-Amino benzoic acid (11) (1.2 g) was added into methanol (12.0 
ml) and stirred the mixture until the solid dissolved. Slowly added 
1.0 ml concentrated H2SO4 to mixture and a precipitate was formed. 
A reflux condenser was attached to the flask, and the mixture was 
heated at a gentle reflux for 60-75 min. The solid was dissolved as it 
undergoes reaction. After completion of the reflux, the reaction 
mixture was allowed to cool to room temperature. Poured the 
reaction mixture into ice water (30.0 ml). While stirring this mixture, 
10% sodium carbonate solution (10.0 ml) was added.Gas evolution 
was observed as the acid was neutralized, the final pH was 
approximately 8. Vacuum filtered the resulting precipitates, and 
washed the product with water. The product was recrystalised with 
n-hexane and again vacuum filtered the resulting precipitates and 
allowed it to dry. Yield: 89. 67%. 
 
Synthetic Procedure for Polymerization of low molecular 
weight Polydichlorophosphazene   
 
The Pyrex glass tubes were soaked in chromic acid solution for 24 
hr, washed by using distilled water and dried at 140 ˚C in an oven. 
The vacuum line was attached to dried tube, evacuated and flamed 
out. Thereafter, hexachlorocycotriphosphazenes (9) (5.0g,) was 
loaded in the tube using 5 % anhydrous aluminium chloride as 
catalyst. The tube was then sealed after evacuation for 1 hr. The 
sealed tube was then heated in a muffle furnace at 250 ± 5 ˚C and 
agitated at regular intervals to stir the melted reactant. After 
completion of polymerization for the required time period, the tube 
was then cooled and shifted to dry box filled with nitrogen gas. 
 
Synthesis of Substituted Polyphosphazenes with p-
Amino benzoic acid ester  
 
The tube was broken, and polymer (polydichlorophosphazenes) 
(10) (0.58 g) was dissolved in dry tetrahydrofuran to carry out 
further substitution reactions. Thereafter, p-aminobenzoic acid ester 
(12) (0.765 g) was transferred to solution of polmer. Freshly distilled 
triethylamine (10.0 ml) was added into the polymer solution followed 
by drop wise solution of ethyl 4-aminobenzoate (0.172 g) in 
tetrahydrofuran (200 ml). The reaction mixture was refluxed for 170 
hr, cooled to room temperature and filtered to remove hydrochloride 
salts. The clear filtrate was concentrated under vacuum and 
precipitation by petroleum ether (60-80 ˚C) to get the product. Yield: 
62% [18]. 
 
Kumar et al. International Journal of Drug Delivery 9 (2) 36-46 [2017] 
 
 
  
PAGE | 38 | 
 
 
Hydrolysis ofp-Aminobenzoic acid ester  
 
P-Amino benzoic acid ester (14)(1.0 g) was added into 10% 
aqueous sodium hydroxide solution (15.0 ml). Boiled the mixture 
under reflux until the molten ester has disappeared completely for 
about one hour. Poured 10% sodium hydroxide solution (3.0 ml) 
down the condenser to dislodged the ester and continued the 
boiling for further 10 min. until the solution was cleared. The solution 
was cooled in ice cold water and  dilute sulphuric acid was added 
with continue stirring until a faint but permanent precipitates of 
benzoic acid was produced and it was tested with litmus - paper to 
ensured that solution was acidic. Thereafter, dilute sodium 
carbonate solution was added with vigorous stirring until the 
precipitates just redissolved and again was tested with litmus - 
paper to ensure that solution was basic. The solution was extracted 
twice with ether (tetrahydrofuran), both aqueous and ether layers 
were separated into beaker and ether layer was distilled off. Pour 
the remainder of whilst hot into evaporating – basin, the phenol was 
crystallised when the residual ether was evaporated. Hydrochloric 
acid was added on to the aqueous solution, the sodium carbonate 
was first neutralised and then benzoic acid was precipitated. The 
solution was filtered and precipitates were washed with water and 
then recrystallized with boiling water. Yield was found to be 78.43% 
[19]. 
 
Procedure for Preparation of Polymer- Drug Conjugate 
of p-Amino benzoic acid ester  
 
Substitued polyphosphazenes (14) (1.0 g) was dissolved in dry 
tetrahydrofuran (100.0 ml) and placed in round bottom flask. 
Lumifantrine (8) (0.05 g) was transferred into the polymeric solution 
containing tetrahydrofuran and triethylamine (1.0 ml) was added on 
it, and then refluxed the solution for 72 hr. Yield: 66.92%. 
 
Preparation of Polymer-Drug Conjugate of Glycine 
Methyl Ester  
 
Synthesis of Glycine methyl ester hydrochlorides  
 
Thionyl chloride (1.4 ml) was added to methanol (100.0 ml) slowly at 
0 °C. Glycine methyl (16) (2.0 g) was added to solution. The 
resulting mixture was refluxed for 8-10 hr at ambient temperature. 
Solvent was evaporated and the residue was triturated with ether at 
0 °C until excess dimethyl sulphite was removed. The crude product 
was crystallized from methanol and ether at 0 °C to get pure Glycine 
methyl ester hydrochloride (17).Yield: 94.34% [20]. 
 
Synthesis of Polyphosphazene Conjugated Glycine 
methyl ester  
Polydichlorophosphazene (2.0 g) was dissolved in tetrahydrofuran 
(200.0 ml). Glycine methyl ester hydrochloride (17) (5.0 g) was 
suspended in tetrahydrofuran (100.0 ml) and triethylamine (20.0 ml) 
was added. This suspension was refluxed for 24 hr, and then 
filtered and added to the polymer solution. The resultant solution 
was stirred at room temperature for 24 hr, and then refluxed for 48 
hr. The solvent was removed under reduced pressure to yield a 
yellow solid. Yield: 72% [21]. 
 
Hydrolysis of Polyphosphazene Conjugated Glycine 
methyl ester  
 
Polyphosphazene Conjugated Glycine methyl ester (20) (1.0 g) was 
transferred in 10% aqueous sodium hydroxide solution (15.0 
ml).Boiled the above mixture uder reflux until the molten ester has 
disappeared completely for about 1hr. Poured 10% sodium 
hydroxide solution (3.0 ml) down the condenser to dislodged the 
ester and continued the boiling for further 10 min. until the solution 
was cleared. The solution was cooled in ice cold water and  dilute 
sulphuric acid was added with continue stirring until a faint but 
permanent precipitates of benzoic acid was produced and was 
tested with litmus - paper to ensured that solution was acidic. 
Thereafter, dilute sodium carbonate solution was added with 
vigorous stirring until the precipitates were just redissolved and 
again was tested with litmus - paper to ensured that solution was 
basic. The solution was extracted twice with tetrahydrofuran, both 
aqueous and ether layers were separated into beaker and ether 
layer was distilled off. Pour the remainder of whilst hot into 
evaporating – basin, the phenol was crystallised when the residual 
ether was evaporated. Hydrochloric acid was added on to the 
aqueous solution, the sodium carbonate was first neutralised and 
then benzoic acid precipitated. The solution was filtered and 
precipitates were washed with water and was recrystallized with 
boiling water. Yield: 81.87% [6].  
 
Procedure for Preparation of Polymer-Drug Conjugates 
of Glycine methyl ester  
  
Substituted polyphosphazenes (20) (1.0 g) was dissolved into dry 
tetrahydrofuran (100.0 ml). Lumifantrine (8) (0.05 g) was transferred 
into the polymeric solution containing tetrahydrofuran and  
triethylamine (1.0 ml) was added on it, and then refluxed the 
solution for 72 hr. After refluxing, the solution was filtered and was 
evaporated to remove out the solvent. Yield: 69.32%. 
 
Evaluation Parameters  
 
Drug Content Percentage 
Kumar et al. International Journal of Drug Delivery 9 (2) 36-46 [2017] 
 
 
  
PAGE | 39 | 
 
 
Polymer- Drug Conjugates of p-Amino benzoic acid 
ester  
 
Polymer-Drug Conjugate of p-Amino benzoic acid ester (15) (5.0 
mg) was transferred into centrifuged tube and methanol (1.0 ml) 
was added on it. The solution was centrifuged for 15 min. at 2000 
rpm in centrifuged apparatus. After the completion of centrifugation, 
1.0 ml solution was removed from tube and transferred into 
volumetric flask (10.0 ml) and volume was made up with methanol. 
Again 1.0 ml solution was removed from above volumetric flask and 
transferred into another 10.0 ml flask and again the volume was 
made up to 10.0 ml with methanol. The absorbance of each solution 
was measured spectrophotometrically at 234 nm. 
 
Polymer-Drug Conjugates of Glycine methyl ester  
 
Polymer-Drug Conjugate of Glycine methyl ester (21) (5.0 mg) was 
transferred into centrifuged tube and methanol (1.0 ml) was added 
on it. The solution was centrifuged for 15 min. at 2000 rpm in 
centrifuged apparatus. After the completion of centrifugation 1.0 ml 
solution was removed from tube and transferred into volumetric 
flask (10.0 ml) and volume was made up with methanol. Again 1.0 
ml solution was removed from above volumetric flask and 
transferred into another 10.0 ml flask and again the volume was 
made upto 10.0 ml with methanol. The absorbance of each solution 
was measured spectrophotometrically at 234 nm. 
 
In-vitro drug release study 
 
In-vitro drug release study of Lumefantrine (Polymer- Drug 
Conjugates of p-Amino benzoicacid ester and Glycine methyl ester) 
was performed in phosphate buffer of pH 7.4 and 0.1 N HCl by 
using dialysis bag method, dialysis membrane having pore size 2.4 
nm and a molecular weight cut off 12000-14000 Dalton (HiMedia, 
India) were used. The dialysis membrane was pre-treated with 
sodium bicarbonate and was washed with distilled water prior to 
use. Formulation of Lumefantrine (5.0 mg) was placed in dialysis 
bag and was immersed in phosphate buffer pH 7.4 (100.0 ml) and 
bag membrane was sealed and placed into 100.0 ml of phosphate 
buffer solution pH 1.2 in a beaker. The beaker was placed on a 
magnetic stirrer at 37 °C at 100 rpm. At predetermined time 
intervals, 5 ml of the sample was taken out and replaced with fresh 
phosphate buffer solution pH 7.4 and the same procedure was 
repeated for 0.1 N HCl.  The drug concentration was determined by 
UV–Visible spectro photometer (Shimadzu UV-1800) at 200-400 nm 
and percent release drug was measured by using formula as given 
below [5]. 
 
% Release of Lumifantrine = 
    	  	            	  	         	     
     	    	  	            
x100 
Result and Discussion    
Synthesis, Characterization and Drug Release Profile of 
Polymer-Drug Conjugates of Lumifantrine (8) by using p-
Amino benzoic acid ester  
Synthesis of Polydichlorophosphazenes  
Polyphosphazenes used as a polymeric backbone has been 
synthesized by thermal polymerization 
ofhexachlorocyclotriphosphazene (9) (prepared by reacting 
ammonium chloride and phosphorus pentachloride). The sealed 
tube was then heated in a muffle furnace at 240 ± 5 ˚C and agitated 
at regular intervals to stir the melted reactant. IR (KBr) cm-1: 1218 
(P=N str.). 
N
P
N
P
N
P
Cl Cl
Cl
Cl
Cl
Cl
P N
Cl
Cl n
240±5C
Anhyd. AlCl3
 
(9)                                                                          (10) 
Synthesis and Characterization of Polymer-Drug 
Conjugates p-Amino benzoic acid ester  
Esterification of p-Amino benzoic acid ester  
P-Amino benzoic acid (11) (1.2 g) was added into methanol (12.0 
ml) and stirred the mixture until the solid dissolved. Slowly added 
1.0 ml concentrated H2SO4 to mixture and a precipitate was formed. 
A reflux condenser was attached to the flask, and the mixture was 
heated at a gentle reflux for 60-75 min. 10% sodium carbonate 
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solution (10.0 ml) was added. IR (KBr) cm-1: 3460.05 (N-H str.), 
3363.16 (O-H str., -COOH), 1664.99 (-C=O str., carboxylic), 1600 
(C=C str., aromatic), 1127.75 – 1311.55 (C-O str., carboxylic). Yield 
of the product was found to be 90.21%. 
COOH
NH2
H2SO4/ Na2CO3
COOCH3
NH2
CH3OH
 
(11)                                                                    (12) 
Synthesis of Substituted Polyphosphazenes with p-
Amino benzoic acid ester  
Polydiclorophosphazene(10) (0.58 g) was dissolved in dry 
tetrahydrofuran to carry out further substitution reactions. 
Thereafter, p-amino benzoic acid ester (12) (0.765 g) was 
transferred to solution of polmer. Freshly distilled triethylamine (10.0 
ml) was added into the polymer solution followed by dropwise 
solution of ethyl 4-aminobenzoate (0.172 g) in tetrahydrofuran (200 
ml).IR (KBr) cm-1: 3350 – 3400 (N-H str.), 1286 (P=N str.), 1719 
(C=O str.), 1175 (C-O str.), 852 (C-H str., bending). Yield: 62%. 
COOCH3
NH2
+
P N
Cl
Cl n
(10)
TEA/ THF
P
NH
NH
N
COOCH3
COOCH3
n
(13)
(12)
 
Hydrolysis of Substituted Polyphosphazenes with p-
Amino benzoic acid ester  
 
Substituted Polyphosphazenes with p-Amino benzoic acid ester 
(14)(1.0 g) was added into 10% aqueous sodium hydroxide solution 
(15.0 ml). Dilute sodium carbonate solution was added and the 
solution was extracted twice with ether (tetrahydrofuran) and both 
the layers were separated. Hydrochloric acid was added on to the 
aqueous solution. 
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P
NH
NH
N
COOCH3
COOCH3
n
P
NH
NH
N
COOH
COOH
n
Hydrolysis
 
(13)                                                                    (14) 
Synthesis of Polymer-Drug Conjugates of Lumifantrine 
p-Aminobenzoic acid ester  
 
Substituted polyphosphazenes (14) (1.0 g) was dissolved in dry 
tetrahydrofuran (100.0ml) and placed in round bottom flask. 
Lumifantrine (8) (0.05 g) was transferred into the polymeric solution 
containing tetrahydrofuran and triethylamine (1.0 ml) was added on 
it. IR (KBr) cm-1: 3359.41 (-NH str.), 2921.76 (C-H str., aliphatic), 
1736.73 (-C=O str., ester), 1492.24 (-C=C- str., aromatic), 1379.74 
(C-Cl), 1235 (P=N, str.), 1063.80 (C-O str., ester).Yield: 66.92%. 
 
P
NH
NH
N
COOH
COOH
n
Cl
Cl
N
HO
Cl
+
Dry THF
 +
TEA
(14)
(8)
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C
O
O
N(CH2CH2CH2CH3)2
Cl
Cl
NH
P N
NH
C O
O
Cl
Cl
Cl
N(CH2CH2CH2CH3)2
Cl
n
 
(15) 
1H NMR (CDCl3)δ(ppm): 
1.87-2.51(6H, m, br, -CH3), 3.34-4.36(4H, m, br, -CH2), 7.69(2H, 
NH). 
 
Drug release profile Lumifantrine from Polymer linked 
antimalarial Drug Conjugates   
 
Drug release profile Polymer-Drug conjugates of antimalarial drug 
was carried out by doing drug content percent and in-vitro drug 
release studies. 
 
Drug Content Percentage 
 
The drug content percentage of Lumifantrine was determined by 
adding (5.0) mg of Polymer-Drug Conjugates (p-Amino benzoic acid 
ester) in 10.0 ml of Methanol. The solution was centrifuged for 15 
min. at 2000 rpm. The absorbance of solution was measured 
spectrophotometrically at 234 nm. The percent drug content of 
Lumifantrine was found to be 89.32% in p-Amino benzoic acid ester 
Polymer-Drug Conjugate, respectively. Lumifantrine was found to 
be uniformly distributed in the Polymer-Drug Conjugate.  
 
In vitro Drug Release Studies 
 
Drug release studies have been known to be important for ensuring 
the sustained release performance and reproducibility of rate and 
duration of drug release. The release study of Polymer-Drug 
Conjugate (p-Amino benzoic acid ester) was carried out in 
phosphate buffer solution pH 7.4 and 0.1 N HCl solution by using 
Dialysis bag membrane having pore size 2.4 nm and a molecular 
weight cut off 12000-14000 Dalton (Hi Media, India). The beaker 
was placed on a magnetic stirrer at 37 °C at 100 rpm with hot plate 
using receptor medium. Phosphate buffer solution pH 7.4 was 
added to maintained sink conditions during release study and 1% 
(w/w) drug was loaded and drug release was checked. Same 
procedure was repeated for 0.1 N HCl solutions. The percent 
cumulative release of drug in 72 hr 88.52% of polymer-Drug 
Conjugate of p-Amino benzoic acid ester release and in 8 hr 
6.001% in 0.1 N HCl. 
 
Synthesis, Characterization and Drug Release Profile of 
Polymer-Drug Conjugate of Lumifantrine (8) by using 
Glycine methyl ester  
Synthesis and Characterization of Polymer-Drug 
Conjugate Glycine methyl ester (21) 
Esterification of Glycine methyl  
Thionyl chloride (1.4 ml) was added to methanol (100.0 ml) slowly at 
0 °C. Glycine methyl (18) (2.0 g) was added to solution and refluxed 
for 8-10 hr. IR (KBr) cm-1: 3391.83 (-NH str.), 2969.34 (-CH- str., 
aliphatic), 1742.42 (-C=O str., ester), 1052.45 (C-O str.).  
Yield: 94.34% 
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H2N CH2 COOH
SOCl2
CH3OH
H2N .CH2 . COOCH3 . HCl
.
H2N . CH2 . COOCH3
Dry
THF
(17)(16)
   
  (18)
Synthesis of Substituted Polyphosphazenes with 
Glycine methyl ester  
 
Polydichlorophosphazene (2.0 g) was dissolved in tetrahydrofuran 
(200.0ml). Glycine methyl ester (18) (5.0 g) was suspended in 
tetrahydrofuran (100.0 ml) and triethylamine (20.0 ml) was added 
and refuxed for 48 hrs.IR (KBr) cm-1: 2896.52 (-CH str., aliphatic), 
1744.11 (-C=O str., ester), 1235.68 (P=N str.), 1433.96 (-NH 
bending). Yield: 72%. 
H2N . CH2 . COOCH3 + P N
Cl
Cl n
P N
NH
NH
CH2
CH2
COOCH3
COOCH3
n
(10)
TEA/ THF
(19)
(18)
 
Hydrolysis of Substituted Polyphosphazenes with 
Glycine methyl ester  
 
Substituted Polyphosphazenes with Glycine methyl ester (20) (1.0 
g) was added into 10% aqueous sodium hydroxide solution (15.0 
ml). Dilute sodium carbonate solution was added and the solution 
was extracted twice with ether and both the layers were separated. 
Hydrochloric acid was added on to the aqueous solution. IR (KBr) 
cm-1: 3493.01 (-NH str.), 2979.31 (-CH2- str., aliphatic), 1735.76 (-
C=O str., carboxylic), 1440.91 (-NH, bending), 1232.69 (-P=N, str.), 
1025.10 (C-O STR.). Yield: 81.87%. 
 
Kumar et al. International Journal of Drug Delivery 9 (2) 36-46 [2017] 
 
 
  
PAGE | 44 | 
 
 
Synthesis of Polymer-Drug Conjugates of Lumifantrine 
Glycine methyl ester  
 
Substituted polyphosphazenes (20) (1.0g) was dissolved into dry 
tetrahydrofuran (100.0ml). Lumifantrine (8) (0.05 g) was transferred 
into the polymeric solution containing tetrahydrofuran and  
triethylamine (1.0ml) was added on it, and then refluxed the solution 
for 72 hr. IR (KBr) cm-1: 3375.44 (-NH str.), 2979.83 (-CH str., 
aliphatic), 1767.77 (-C=O str., ester), 1614.16 (-C=C- str., aromatic), 
1392.66 (-C-Cl str.), 1259.01 (P=N str.), 1069.82 (C-O str., ester). 
Yield: 69.32%. 
1H NMR (CDCl3)δ(ppm) : 0.85-4.12 (4H, m , br, aliphatic protons, 
6.69-6.79 (26H, m, br, -ArH) and 9.15 (2H, br, -NH). 
 
COOH
CH2
NH
P
NH
CH2
COOH
N
Cl
Cl
N
HO
Cl
n
+
 
(20)                                                                          (8) 
Dry THF
Triethylamine
 
CH2
C
O
O
N(CH2CH2CH2CH3)2
Cl
Cl
Cl
NH
P
NH
N
CH2
C O
O
N(CH2CH2CH2CH3)2
Cl
Cl
Cl
*
n
 
(21) 
Kumar et al. International Journal of Drug Delivery 9 (2) 36-46 [2017] 
 
 
  
PAGE | 45 | 
 
 
Drug release profile of Lumifantrine (8) from Polymer 
linked antimalarial Drug Conjugates  
 
Drug Content Percentage 
 
The drug content percentage of Lumifantrine was determined by 
adding 5.0 mg of Polymer-Drug Conjugates (Glycine methyl ester) 
in 10.0 ml of Methanol. The solution was centrifuged for 15 min. at 
2000 rpm. The absorbance of each solution was measured 
spectrophotometrically at 234 nm. The % drug content of 
Lumifantrine was found to be 87.55% in Glycine methyl ester 
Polymer-Drug Conjugates, respectively. The Lumifantrine was 
found to be uniformly distributed in the Polymer-Drug Conjugates.  
In-vitro Drug Release Studies 
 
The release study of Polymer-Drug Conjugate (Glycine methyl 
ester) was carried out in phosphate buffer solution pH 7.4 and 0.1 N 
HCl solution by using Dialysis bag membrane having pore size 2.4 
nm and a molecular weight cut off 12000-14000 Dalton (Hi Media, 
India). The beaker was placed on a magnetic stirrer at 37 °C at 100 
rpm with hot plate using receptor medium. Phosphate buffer 
solution pH 7.4 was added to maintained sink conditions during 
release study and 1% (w/w) drug was loaded and drug release was 
checked. The percent cumulative release of drug in phosphate 
buffer pH 7.4 is shown in Figure-1.  
 
 
Figure 1: Comparison between In-vitro Drug Release of Lumifantrine p-Amino benzoic acid ester and Lumifantrine Glycine methyl ester in pH 7.4 
The release study showed the drug release increased with the 
increasing time in hrs by using the formula cumulative % drug 
release was calculated. From the release curve of p-Amino benzoic 
acid and Glycine methyl ester clearly observed that p-Amino 
benzoic acid showed better drug release per hr. as well as % 
cumulative release in 72 hrs in phosphate buffer pH 7.4 as 
comparison to 0.1 N HCl. This may be due to higher dissolution of 
the formulation due to which more amount of drug escapes into the 
outer environment. 
 
Conclusion 
 
The polymer-linked Conjugates of Lumifantrine: p-Amino benzoic 
acid ester and Glycine methyl ester substituted polyphosphazene 
drug conjugates have been found to have drug content 89.32% and 
87.55% , respectively. 
Drug release profile of polyphosphazene-linked conjugates of 
Lumifantrine has been studied at pH 7.4 at the time intervals of 1, 2, 
4, 8, 12, 24, 48 and 72 hr and at pH 1.2 at time intervals of 1, 2, 4 
and 8 hr. The in-vitro drug release of Lumifantrine drug conjugates: 
p-Amino benzoic acid ester substituted polyphosphazene drug 
conjugate (15) and Glycine methyl ester substituted 
polyphosphazene drug conjugate (21) have been found to be 6.00 
% and 5.96% (pH 1.2), 88.52% and 79.86% (pH 7.4), respectively. 
Therefore, from these studies, it could be concluded that p-Amino 
benzoic acid ester substituted polyphosphazene drug conjugate 
(15) has slightly better drug release profile as compared to the 
Glycine methyl ester substituted polyphosphazene drug conjugate 
(21).  
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